Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Antimicrobial Agents and Chemotherapy|October 28, 2005
Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activityPatrick Dorr, Mike Westby, Susan Dobbs, et al.
Methods in Enzymology|May 19, 2009
CCR5 pharmacology methodologies and associated applicationsRoy Mansfield, Sarah Able, Paul Griffin, et al.
Journal of Medicinal Chemistry|January 30, 2009
Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlaysLyn H Jones, Gill Allan, Oscar Barba, et al.
Antiviral Therapy|May 11, 2011
Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patientsJonathan M Schapiro, Charles A B Boucher, Daniel R Kuritzkes, et al.
Antimicrobial Agents and Chemotherapy|March 10, 2022
Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to FluoroquinolonesGregory S Basarab, Sandeep Ghorpade, Liezl Gibhard, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2009
Design and optimisation of potent gp120-CD4 inhibitorsThien-Duc Tran, Fiona M Adam, Frederick Calo, et al.
Bioorganic & Medicinal Chemistry Letters|July 22, 2009
Discovery of a small molecule inhibitor through interference with the gp120-CD4 interactionDavid H Williams, Fiona Adam, David R Fenwick, et al.
Plos Pathogens|December 21, 2010
HIV capsid is a tractable target for small molecule therapeutic interventionWade S Blair, Chris Pickford, Stephen L Irving, et al.
Journal of Medicinal Chemistry|December 7, 2010
An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798)Paul A Stupple, David V Batchelor, Martin Corless, et al.
Scientific Reports|July 15, 2015
Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerasesGregory S Basarab, Gunther H Kern, John McNulty, et al.
Pageof 3